Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Arman Ajami"'
Autor:
Ozra TABATABAEI-MALAZY, Masumeh NORANI, Ramin HESHMAT, Mostafa QORBANI, Afsaneh VOSOOGH, Behnaz AFRASHTEH, Farzin KAHKESHAN, Arman AJAMI, Bagher LARIJANI
Publikováno v:
Iranian Journal of Public Health, Vol 47, Iss 9 (2018)
Background: Due to high cost and burden of osteoporosis, it is reasonable to focus on the reduction of fractures as the main goal of treatment. We compared the efficacy and safety of a new biosimilar recombinant human parathyroid hormone (CinnoPar®,
Externí odkaz:
https://doaj.org/article/bb8fa7579b3644c292a8a208fe7f17ff
Autor:
Mirhamed Hajimiri, Arman Ajami, Bereket Molla Tigabu, Nikinaz Ashrafi Shahmirzadi, Nima Sepehri, Pardis Zaboli, Monireh Afzali
Publikováno v:
Journal of Pharmaceutical Research International. :1-8
Background and Objectives: Prostate cancer is an ever-increasing global incidence and has become the fifth leading cause of cancer-related mortality in men. A significant number of patients with prostate cancer develop metastatic castration-resistant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dbda5ba1770f34a2102f95d0a4f9dcbf
https://doi.org/10.9734/jpri/2019/v31i630324
https://doi.org/10.9734/jpri/2019/v31i630324
Autor:
Naser Kokhaei, Ghasem Mosayebi, Arman Ajami, Majid Mirmohammadkhani, Parviz Kokhaei, Nabiollah Asghari, Fereshteh Ashtari, Farhad Bahraminia, Mehdi Sadat Akhavi, Mahdieh Shokrollahi Barough
Publikováno v:
International Immunopharmacology. 62:109-113
Introduction Human recombinant interferon beta (IFN-β) is one of the first line treatments for Relapsing-Remitting Multiple Sclerosis (RRMS). However, the production of neutralizing antibodies (NAb) can impair its function. The aim of this study was
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16273ec5f59c8ff8a6441ed1fdda8d27
https://doi.org/10.1016/j.intimp.2018.06.032
https://doi.org/10.1016/j.intimp.2018.06.032